|
Cambrios Technologies Corporation, formed in 2003, is known for its application development platform, which is based on the directed-evolution technology invented by company co-founder Dr. Angela Belcher of MIT. The firm's other founder, Dr. Evelyn Hu, of the University of California at Santa Barbara, has acquired licensing rights to the technology. Cambrios Technologies employs molecular biology techniques in streamlining manufacturing processes. The company's development platform discovers peptide agents that control the synthesis and assembly of inorganic materials. The system supports the creation of biomorphic nanostructures from a variety of materials. Molecular affinity supports the precise assembly of nanostructures. Cambrios Technologies targets its platform to companies across the electronics, chemicals, coatings, and health care industries. Investors include ARCH Venture Partners, Alloy Ventures, Oxford Bioscience Partners, Lux Capital, and Avalon Ventures. The firm has secured over $12 million in two rounds of funding.
|
Information Sources, Inc.